Drug Development for Neglected Diseases — The Trouble with FDA Review Vouchers

A new federal program will give the sponsor of a drug for a tropical disease a “voucher” entitling the company to expedited FDA review of a new drug application for any other product it makes. Dr. Aaron Kesselheim writes that as enacted, however, priority-review vouchers represent an inefficient and potentially dangerous way of encouraging research into tropical diseases.